Background Background Selective serotonin
Selective serotonin reuptake inhibitors are effective in the reuptake inhibitors are effective in the treatment of social anxiety disorder and treatment of social anxiety disorder and are currently regarded as the are currently regarded as the pharmacotherapy of choice. pharmacotherapy of choice.
Aims Aims To investigate the efficacy and
To investigate the efficacy and tolerability of escitalopram in the tolerability of escitalopram in the treatment of generalised social anxiety treatment of generalised social anxiety disorder. disorder.
Method Method Patients with generalised
Patients with generalised social anxiety disorder were randomised social anxiety disorder were randomised to receive placebo ( to receive placebo (n n¼177) or10^20 mg 177) or10^20 mg escitalopram ( escitalopram (n n¼181) in a12-week, 181) in a12-week, double-blind trial.The primary outcome double-blind trial.The primary outcome measure was the mean change from measure was the mean change from baseline to last assessment in the baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) Liebowitz Social Anxiety Scale (LSAS) total score. total score.
Results

The study showed a statistically
The study showed a statistically superior therapeutic effect for superior therapeutic effect for escitalopram compared with placebo on escitalopram compared with placebo on the LSAS total score ( the LSAStotal score (P P¼0.005 ).There 0.005).There were significantly more responders to were significantly more responders to treatment for escitalopram than for treatment for escitalopram than for placebo (54% placebo (54% v v. 39%; . 39%; P P5 50.01).The clinical 0.01).The clinical relevance of these findings was supported relevance of these findings was supported by significant reduction in the work and by significant reduction in the work and social components of the Sheehan social components of the Sheehan Disability Scale and by the good Disability Scale and by the good tolerability of escitalopram treatment. tolerability of escitalopram treatment.
Conclusions Conclusions Escitalopram was
Escitalopram was efficacious and well tolerated in the efficacious and well tolerated in the treatment of generalised social anxiety treatment of generalised social anxiety disorder. disorder.
Declaration of interest Declaration of interest The study
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Social phobia or anxiety disorder is increasSocial phobia or anxiety disorder is increasingly recognised as a highly prevalent and ingly recognised as a highly prevalent and chronic disorder with onset during the teenchronic disorder with onset during the teenage years (Lepine & Pelissolo, 1996 ; age years (Lépine & Pélissolo, 1996; Wittchen Wittchen et al et al, 1999) . Although the disor-, 1999). Although the disorder is associated with significant disability der is associated with significant disability (including educational and occupational) (including educational and occupational) which has a negative impact on quality which has a negative impact on quality of life, it is both underdiagnosed and of life, it is both underdiagnosed and undertreated . Early work undertreated . Early work demonstrated that monoamine oxidase demonstrated that monoamine oxidase inhibitors (e.g. phenelzine) were effective inhibitors (e.g. phenelzine) were effective in the treatment of the disorder, but these in the treatment of the disorder, but these agents are limited by their side-effect proagents are limited by their side-effect profile, the need for dietary precautions, and file, the need for dietary precautions, and drug interactions (Versiani, 2000) . More drug interactions (Versiani, 2000) . More recent work has established the efficacy of recent work has established the efficacy of several selective serotonin reuptake inhibiseveral selective serotonin reuptake inhibitors (SSRIs) (Stein tors (SSRIs) (Stein et al et al, 1999; Van , 1999; Van Ameringen Ameringen et al et al, 2001; Liebowitz , 2001; Liebowitz et al et al, , 2002) and these agents have been 2002) and these agents have been recommended as first-line pharmacorecommended as first-line pharmacotherapy (Ballenger therapy (Ballenger et al et al, 1998) . This study , 1998). This study investigates the efficacy and tolerability of investigates the efficacy and tolerability of escitalopram in the treatment of generalised escitalopram in the treatment of generalised social anxiety disorder. social anxiety disorder.
METHOD METHOD Study design and dosing schedule Study design and dosing schedule
This multinational study was a randomised, This multinational study was a randomised, parallel group, placebo-controlled trial parallel group, placebo-controlled trial involving 41 centres in eight countries involving 41 centres in eight countries (Austria, Canada, Denmark, Finland, (Austria, Canada, Denmark, Finland, Germany, Norway, South Africa and the Germany, Norway, South Africa and the UK). Patients who met selection criteria UK). Patients who met selection criteria entered a 1-week, single-blind, placebo entered a 1-week, single-blind, placebo lead-in period before being randomised to lead-in period before being randomised to 12 weeks of double-blind treatment with 12 weeks of double-blind treatment with escitalopram or matched placebo capsules. escitalopram or matched placebo capsules. Patients were contacted for a safety Patients were contacted for a safety follow-up 30 days after their last dose. follow-up 30 days after their last dose. The initial dosage of escitalopram was The initial dosage of escitalopram was 10 mg per day. The dosage could be in-10 mg per day. The dosage could be increased to 20 mg per day after 4, 6 or 8 creased to 20 mg per day after 4, 6 or 8 weeks of treatment in case of an unsatisfacweeks of treatment in case of an unsatisfactory response, judged as a score above 5 on tory response, judged as a score above 5 on the Clinical Global Impression scale rating the Clinical Global Impression scale rating for severity (CGI-S; Guy, 1976) or no defor severity (CGI-S; Guy, 1976) or no decrease in CGI-S score since baseline. The crease in CGI-S score since baseline. The mean daily dose of escitalopram was mean daily dose of escitalopram was 17.6 mg at week 12. Efficacy and tolerabil-17.6 mg at week 12. Efficacy and tolerability were assessed at baseline and after 1, 2, ity were assessed at baseline and after 1, 2, 3, 4, 6, 8 and 12 weeks of treatment. 3, 4, 6, 8 and 12 weeks of treatment.
Patient population Patient population
The patient population comprised female The patient population comprised female and male out-patients with a primary and male out-patients with a primary diagnosis of generalised social anxiety disdiagnosis of generalised social anxiety disorder established by means of a diagnostic order established by means of a diagnostic interview following DSM-IV criteria interview following DSM-IV criteria (American Psychiatric Association, 1994) , (American Psychiatric Association, 1994) , using the Mini-International Neuropsychiausing the Mini-International Neuropsychiatric Interview (MINI; Sheehan tric Interview (MINI; Sheehan et al et al, 1998) , 1998) to assist in the exclusion of disallowed coto assist in the exclusion of disallowed comorbidity. The patients were mainly morbidity. The patients were mainly recruited through advertisements. At the recruited through advertisements. At the screening visit, patients 18-65 years old screening visit, patients 18-65 years old were selected if they had a total score of were selected if they had a total score of at least 70 on the Liebowitz Social Anxiety at least 70 on the Liebowitz Social Anxiety Scale (LSAS; with exhibScale (LSAS; with exhibited fear or avoidance traits in at least four ited fear or avoidance traits in at least four social situations, and were otherwise social situations, and were otherwise healthy based on a physical examination. healthy based on a physical examination. Patients were excluded if they had another Patients were excluded if they had another Axis I disorder that was considered the priAxis I disorder that was considered the primary diagnosis within the previous 6 mary diagnosis within the previous 6 months, if the investigator diagnosed a sermonths, if the investigator diagnosed a serious risk of suicide or if the Montgomeryious risk of suicide or if the MontgomeryAsberg Depression Rating Scale (MADRS; Å sberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979) total score Montgomery & Å sberg, 1979) total score was higher than 19. Patients were also exwas higher than 19. Patients were also excluded if they had a DSM-IV diagnosis of cluded if they had a DSM-IV diagnosis of alcohol or drug misuse during the past 6 alcohol or drug misuse during the past 6 months, or if they had taken a psychoactive months, or if they had taken a psychoactive drug (including any type of antidepressant, drug (including any type of antidepressant, beta-blocker, benzodiazepine, narcotic, beta-blocker, benzodiazepine, narcotic, analgesic, antipsychotic or herbal remedy) analgesic, antipsychotic or herbal remedy) within 2 weeks (5 weeks for fluoxetine within 2 weeks (5 weeks for fluoxetine and 6 months for depot neuroleptics) and 6 months for depot neuroleptics) before screening, or if the patient had a before screening, or if the patient had a positive urine drug screen for opiates, positive urine drug screen for opiates, methadone, cocaine, amphetamines or methadone, cocaine, amphetamines or benzodiazepines. The only allowed concobenzodiazepines. The only allowed concomitant use of a psychotropic drug during mitant use of a psychotropic drug during the study was chloral hydrate taken as a the study was chloral hydrate taken as a hypnotic but not for more than three consehypnotic but not for more than three consecutive nights. Furthermore, patients with a cutive nights. Furthermore, patients with a diagnosis of mania or hypomania, body diagnosis of mania or hypomania, body dysmorphic disorder, schizophrenia/other dysmorphic disorder, schizophrenia/other psychotic disorder, eating disorders, mental psychotic disorder, eating disorders, mental retardation or any Axis II cluster diagnosis retardation or any Axis II cluster diagnosis were also excluded. Patients with a known were also excluded. Patients with a known drug (including citalopram) allergy or drug (including citalopram) allergy or hypersensitivity or a known lack of therahypersensitivity or a known lack of therapeutic response to an adequate trial with peutic response to an adequate trial with 2 2 2 2 2 2 
Efficacy assessments Efficacy assessments
The primary efficacy measure was the The primary efficacy measure was the mean change from baseline to the last mean change from baseline to the last assessment (carried forward) of the LSAS assessment (carried forward) of the LSAS total score. This scale consists of 24 items, total score. This scale consists of 24 items, 13 describing performance situations and 13 describing performance situations and 11 describing social interaction situations 11 describing social interaction situations . Each of the items is . Each of the items is separately rated for 'fear' and 'avoidance' separately rated for 'fear' and 'avoidance' using a four-point categorical scale. All using a four-point categorical scale. All investigators attended supervised group investigators attended supervised group sessions in order to standardise the intersessions in order to standardise the interview and rating techniques. Secondary view and rating techniques. Secondary efficacy measures included: efficacy measures included:
(a) (a) mean change from baseline to each visit mean change from baseline to each visit in the LSAS sub-scale scores for 'fear/ in the LSAS sub-scale scores for 'fear/ anxiety' and 'avoidance'; anxiety' and 'avoidance'; (b) (b) CGI-S score per visit and change from CGI-S score per visit and change from baseline to visit; baseline to visit; (c) (c) Clinical Global Impression -ImproveClinical Global Impression -Improvement (CGI-I) score: proportion of ment (CGI-I) score: proportion of responders to treatment, defined as responders to treatment, defined as patients achieving a score of 1 (very patients achieving a score of 1 (very much improved) or 2 (much improved) much improved) or 2 (much improved) on the CGI-I; on the CGI-I;
(d) (d) Sheehan Disability Scale (SDS; Sheehan, Sheehan Disability Scale (SDS; Sheehan, 1983) score, for the three domains 1983) score, for the three domains 'work', 'social' and 'family'; 'work', 'social' and 'family'; (e) (e) change from baseline to each visit in change from baseline to each visit in MADRS total score (the MADRS MADRS total score (the MADRS consists of ten items, each rated on a consists of ten items, each rated on a scale from 0 to 6). scale from 0 to 6).
Safety and tolerability Safety and tolerability
Safety assessments were based on vital signs Safety assessments were based on vital signs (in a sitting position after 5 min rest), body (in a sitting position after 5 min rest), body weight, clinical laboratory tests (including weight, clinical laboratory tests (including haematology and biochemistry) and haematology and biochemistry) and electrocardiograms (ECGs), and were electrocardiograms (ECGs), and were assessed at the screening visit and at week assessed at the screening visit and at week 12. Adverse events observed by the investi-12. Adverse events observed by the investigator, spontaneously reported by the gator, spontaneously reported by the patient or reported in response to nonpatient or reported in response to nonleading questions were recorded at each leading questions were recorded at each visit. The investigator documented the visit. The investigator documented the relationship to treatment, onset duration relationship to treatment, onset duration and intensity (mild, moderate or severe). and intensity (mild, moderate or severe). All adverse events were coded using the All adverse events were coded using the included term according to the World included term according to the World Health Organization Adverse Reaction Health Organization Adverse Reaction Terminology. Terminology.
Statistical analysis Statistical analysis
Efficacy analyses were based on the full Efficacy analyses were based on the full analysis set (corresponding to the intentanalysis set (corresponding to the intentto-treat population), which comprised all to-treat population), which comprised all randomised patients who took doublerandomised patients who took doubleblind study product and had at least one blind study product and had at least one valid post-baseline assessment of the privalid post-baseline assessment of the primary efficacy measure. Safety analyses mary efficacy measure. Safety analyses were based on the set of all patients treated, were based on the set of all patients treated, which included all patients who took at which included all patients who took at least one dose of double-blind study least one dose of double-blind study product. product. A minimum of 135 patients per treat-A minimum of 135 patients per treatment arm was required to reach a power ment arm was required to reach a power of 90% to detect a significant difference of 90% to detect a significant difference between treatment groups in mean change between treatment groups in mean change from baseline to final assessment in LSAS from baseline to final assessment in LSAS total score at the 5% significance level. A total score at the 5% significance level. A general linear model for analysis of covargeneral linear model for analysis of covariance (ANCOVA) was applied to the iance (ANCOVA) was applied to the primary and secondary efficacy measures primary and secondary efficacy measures with factors for treatment group and with factors for treatment group and centres (all centres with fewer than four centres (all centres with fewer than four patients were collapsed into one collective patients were collapsed into one collective centre), and with baseline LSAS total centre), and with baseline LSAS total score as a covariate. The final CGI-S and score as a covariate. The final CGI-S and CGI-I scores were also analysed using the CGI-I scores were also analysed using the non-parametric Cochran-Mantel-Haenszel non-parametric Cochran-Mantel-Haenszel mean score statistics. Between-group commean score statistics. Between-group comparisons of the proportion of responders parisons of the proportion of responders (CGI-I score of 1 or 2) to treatment were (CGI-I score of 1 or 2) to treatment were performed using chi-squared and Fisher's performed using chi-squared and Fisher's exact tests. Descriptive statistics were used exact tests. Descriptive statistics were used for absolute values and mean changes from for absolute values and mean changes from baseline in laboratory values, ECG parabaseline in laboratory values, ECG parameters, vital signs and body weight. All meters, vital signs and body weight. All statistical tests were two-sided and statistical tests were two-sided and were carried out at the 5% level of were carried out at the 5% level of significance. significance.
RESULTS RESULTS
Patient baseline characteristics Patient baseline characteristics
A total of 358 patients were randomised A total of 358 patients were randomised into the study, 177 to placebo treatment into the study, 177 to placebo treatment and 181 to escitalopram treatment. Of and 181 to escitalopram treatment. Of these, 5 patients did not receive doublethese, 5 patients did not receive doubleblind treatment. The full analysis set thus blind treatment. The full analysis set thus consisted of 177 patients in the escitaloconsisted of 177 patients in the escitalopram group and 176 patients in the placebo pram group and 176 patients in the placebo group. A total of 290 patients (81%) comgroup. A total of 290 patients (81%) completed the study, 145 in each treatment pleted the study, 145 in each treatment group (Fig. 1 ). There were slightly more group (Fig. 1 ). There were slightly more men than women in both treatment groups. men than women in both treatment groups. Baseline characteristics were similar for the Baseline characteristics were similar for the two treatment groups with the exception of two treatment groups with the exception of age and duration of the disorder, both of age and duration of the disorder, both of which were slightly higher in the escitalowhich were slightly higher in the escitalopram group (Table 1) . No between-group pram group (Table 1) . No between-group difference was seen for the severity of the difference was seen for the severity of the disorder, as measured by the baseline LSAS disorder, as measured by the baseline LSAS total score and the CGI score. There was no total score and the CGI score. There was no difference with respect to medical history difference with respect to medical history or physiological variables. Comorbidity or physiological variables. Comorbidity with depressive symptoms was low, as with depressive symptoms was low, as judged by the baseline MADRS total score judged by the baseline MADRS total score and the low number of patients with a diagand the low number of patients with a diagnosis of comorbid depression or dysthymia nosis of comorbid depression or dysthymia (Table 1 ). The high baseline LSAS total (Table 1 ). The high baseline LSAS total score and the baseline SDS score between score and the baseline SDS score between 6 and 7 (on a ten-point scale) for the work 6 and 7 (on a ten-point scale) for the work and social life items are in line with the and social life items are in line with the average CGI-S score, indicating a markedly average CGI-S score, indicating a markedly ill patient population. ill patient population.
Patient withdrawals Patient withdrawals
A total of 68 patients (19%) withdrew A total of 68 patients (19%) withdrew from the study, with no overall betweenfrom the study, with no overall betweengroup difference (18% in the placebo group group difference (18% in the placebo group and 20% in the escitalopram group). Howand 20% in the escitalopram group). However, numerically more patients in the ever, numerically more patients in the escitalopram group (8.8%) than in the escitalopram group (8.8%) than in the placebo group (4.5%) withdrew because placebo group (4.5%) withdrew because of adverse events and numerically more of adverse events and numerically more patients in the placebo group (6.2%) patients in the placebo group (6.2%) than in the escitalopram group (2.2%) than in the escitalopram group (2.2%) withdrew because of lack of efficacy, with withdrew because of lack of efficacy, with the latter difference approaching statistical the latter difference approaching statistical significance ( significance (P P¼0.059). 0.059). 
Efficacy results Efficacy results
Primary efficacy outcome Primary efficacy outcome (Fig. 2) . Exploratory 0.005) (Fig. 2) . Exploratory analyses of potential covariates revealed no analyses of potential covariates revealed no treatment-by-centre or treatment-by-basetreatment-by-centre or treatment-by-baseline LSAS total score interaction effect. line LSAS total score interaction effect. The same was true for treatment The same was true for treatment interactions with gender, age and duration interactions with gender, age and duration of disorder. of disorder.
Secondary efficacy measures Secondary efficacy measures
The mean change from baseline to endThe mean change from baseline to endpoint (LOCF) in the LSAS sub-scale scores point (LOCF) in the LSAS sub-scale scores was statistically significant in favour of was statistically significant in favour of escitalopram at week 12 ( escitalopram at week 12 (P P5 50.05) for 0.05) for 'avoidance' and at weeks 6 and 12 'avoidance' and at weeks 6 and 12 ( (P P5 50.001) for 'fear/anxiety', but not for 0.001) for 'fear/anxiety', but not for the SDS 'family' sub-scale (Table 2) . Superthe SDS 'family' sub-scale (Table 2) . Superiority of escitalopram over placebo was iority of escitalopram over placebo was also manifested in the change from baseline also manifested in the change from baseline to week 12 (LOCF) in CGI-S score to week 12 (LOCF) in CGI-S score ( (P P5 50.01), the mean CGI-I score at week 0.01), the mean CGI-I score at week 12 ( 12 (P P5 50.001) and in the change from 0.001) and in the change from baseline to week 12 (LOCF) in the two baseline to week 12 (LOCF) in the two SDS items 'work' ( SDS items 'work' (P P¼0.01) and 'social' 0.01) and 'social' ( (P P¼0.02) ( Table 2) . 0.02) ( Table 2) . A total of 54% of escitalopram-treated A total of 54% of escitalopram-treated patients and 39% of placebo-treated patients and 39% of placebo-treated patients responded to treatment (LOCF, patients responded to treatment (LOCF, P P5 50.01). The corresponding figures for 0.01). The corresponding figures for the observed case (OC) analysis were 63% the observed case (OC) analysis were 63% of escitalopram-treated patients and 43% of escitalopram-treated patients and 43% of placebo-treated patients ( of placebo-treated patients (P P5 50.001). 0.001). Table 3 shows all treatment-emergent Table 3 shows all treatment-emergent adverse events with an incidence of more adverse events with an incidence of more than 5% in either treatment group. No than 5% in either treatment group. No clinically relevant trend was observed in clinically relevant trend was observed in mean ECG or in clinical laboratory mean ECG or in clinical laboratory parameters. parameters.
Safety results Safety results
DISCUSSION DISCUSSION
Patient population Patient population
The typical onset of social anxiety disorder The typical onset of social anxiety disorder during adolescence, with its chronic course, during adolescence, with its chronic course, its high level of psychiatric comorbidity its high level of psychiatric comorbidity and its low spontaneous remission rate, and its low spontaneous remission rate, contributes to serious impairment of daily contributes to serious impairment of daily functioning in the professional and social functioning in the professional and social life of those with this disorder (Lepine & life of those with this disorder (Lépine & Pelissolo, 2000) . These epidemiological Pélissolo, 2000). These epidemiological characteristics were reflected among our characteristics were reflected among our participants. The mean age of onset was participants. The mean age of onset was 15 years and the chronicity of the disorder 15 years and the chronicity of the disorder was evident from its average duration, was evident from its average duration, which was more than 20 years. Sheehan which was more than 20 years. Sheehan Disability Scale mean baseline scores for Disability Scale mean baseline scores for 'work' and 'social' items (around 7 on the 'work' and 'social' items (around 7 on the ten-point sub-scales) indicate the negative ten-point sub-scales) indicate the negative impact of the disorder on daily life impact of the disorder on daily life functioning in this group. functioning in this group.
In order to investigate the specific effiIn order to investigate the specific efficacy of escitalopram in the treatment of cacy of escitalopram in the treatment of social anxiety disorder, the study selected social anxiety disorder, the study selected a somewhat atypical patient population a somewhat atypical patient population with a low level of comorbidity. The averwith a low level of comorbidity. The average MADRS total score of 7.5 indicates age MADRS total score of 7.5 indicates the absence of significant depressive sympthe absence of significant depressive symptoms. It can thus be concluded that the toms. It can thus be concluded that the patient population in this study represents patient population in this study represents patients with relatively pure, generalised patients with relatively pure, generalised social anxiety disorder. The average LSAS social anxiety disorder. The average LSAS total score at baseline of over 95 indicates total score at baseline of over 95 indicates a more severely ill patient population than a more severely ill patient population than that in other published clinical drug trials that in other published clinical drug trials (Baldwin (Baldwin et al et al, 1999; Liebowitz , 1999; Liebowitz et al et al, 2002) . , 2002).
2 2 4 2 2 4 (53) 94 (53) 101 (56) 101 (56) 195 (55) 195 (55) Women Women 83 (47) 83 (47) 80 (44) 80 (44) 163 (45) 163 (45) Age, years: mean (s.d.) Age, years: mean (s.d.) 36 (11) 36 (11) 39 (11) 39 (11) 38 (11) 38 (11) Age at onset of SAD, years Age at onset of SAD, years 15 (8) 15 (8) 15 (9) 
Therapeutic efficacy and placebo Therapeutic efficacy and placebo response response
This study of the SSRI escitalopram This study of the SSRI escitalopram confirmed the efficacy of SSRIs in the treatconfirmed the efficacy of SSRIs in the treatment of generalised social anxiety disorder. ment of generalised social anxiety disorder. Escitalopram had a significantly better Escitalopram had a significantly better effect than placebo at the end of the 12-effect than placebo at the end of the 12-week trial period on both the primary and week trial period on both the primary and the secondary efficacy measures, including the secondary efficacy measures, including the two LSAS sub-scales of 'fear/anxiety' the two LSAS sub-scales of 'fear/anxiety' and 'avoidance'. The primary analysis and 'avoidance'. The primary analysis showed a decrease in the total LSAS score showed a decrease in the total LSAS score of 34.4 points in the escitalopram group of 34.4 points in the escitalopram group and a relatively large decrease of 27.2 and a relatively large decrease of 27.2 points in the placebo group. The effect size points in the placebo group. The effect size in the escitalopram group is comparable in the escitalopram group is comparable with that reported in other studies of SSRIs with that reported in other studies of SSRIs in the treatment of generalised social in the treatment of generalised social anxiety (Stein anxiety (Stein et al et al, 1998; Allugander, , 1998; Baldwin 1999; Baldwin et al et al, 1999) . However, no , 1999). However, no other published study has reported a other published study has reported a placebo response as high as 39% (LOCF) placebo response as high as 39% (LOCF) in social anxiety disorder. A review by in social anxiety disorder. A review by Oosterbaan Oosterbaan et al et al (2001) analysed 15 (2001) analysed 15 placebo-controlled studies and concluded placebo-controlled studies and concluded that a moderate placebo response is seen that a moderate placebo response is seen in this disorder which appears to be lower in this disorder which appears to be lower than that in depression or panic disorder. than that in depression or panic disorder. The review found no evidence of an inThe review found no evidence of an increase in the placebo response in studies crease in the placebo response in studies of social anxiety over the past decade, of social anxiety over the past decade, although this is seen for other disorders. although this is seen for other disorders. There was, however, a trend towards a There was, however, a trend towards a higher response rate in the placebo groups, higher response rate in the placebo groups, but not in the active treatment groups, with but not in the active treatment groups, with increasing sample size. No relation was increasing sample size. No relation was found between the baseline severity of found between the baseline severity of social anxiety disorder and improvement social anxiety disorder and improvement during treatment, as measured by the mean during treatment, as measured by the mean change from baseline or the percentage of change from baseline or the percentage of responders. This is somewhat in contrast responders. This is somewhat in contrast to other studies of this disorder, in which to other studies of this disorder, in which placebo responders were generally less placebo responders were generally less symptomatic (Montgomery, 1998) and symptomatic (Montgomery, 1998) and where a better separation between active where a better separation between active medication and placebo was seen among medication and placebo was seen among the more severely affected patients. The the more severely affected patients. The trend towards a higher response rate in trend towards a higher response rate in the placebo groups with increasing size of the placebo groups with increasing size of trial, as found by Oosterbaan trial, as found by Oosterbaan et al et al (2001) , (2001), is consistent with the substantial size of is consistent with the substantial size of our trial. our trial.
Irrespective of the placebo response Irrespective of the placebo response size, the clinical significance of the escitalosize, the clinical significance of the escitalopram treatment effects in this study was pram treatment effects in this study was demonstrated by statistically significant demonstrated by statistically significant effects on the global measures of severity effects on the global measures of severity of illness and improvement (CGI-S and of illness and improvement (CGI-S and CGI-I) and, importantly, also on the two CGI-I) and, importantly, also on the two Sheehan Disability Scale items 'work' and Sheehan Disability Scale items 'work' and 'social'. A final score on the CGI-I scale 'social'. A final score on the CGI-I scale of 1 or 2 (very much or much improved) of 1 or 2 (very much or much improved) has commonly been used as a response has commonly been used as a response criterion in social anxiety disorder pharmacriterion in social anxiety disorder pharmacotherapy trials. In this trial, the escitalocotherapy trials. In this trial, the escitalopram response rate (OC) was 63% pram response rate (OC) was 63% compared with 43% in the placebo group. compared with 43% in the placebo group. Again, the magnitude of response of the Again, the magnitude of response of the escitalopram-treated patients is consistent escitalopram-treated patients is consistent with that reported in other studies, whereas with that reported in other studies, whereas the placebo response rate is higher than that the placebo response rate is higher than that found previously (Liebowitz found previously (Liebowitz et al et al, 2002) . , 2002) .
Withdrawals Withdrawals
The total withdrawal rate of 19% is clearly The total withdrawal rate of 19% is clearly lower than that in a recently reported fixedlower than that in a recently reported fixeddose study with paroxetine (Liebowitz dose study with paroxetine (Liebowitz et al et al, , 2002) and somewhat lower than the aver-2002) and somewhat lower than the average rate of 23% based on the 15 studies age rate of 23% based on the 15 studies reviewed by Oosterbaan reviewed by Oosterbaan et al et al (2001) . The (2001) . The latter review further reported a positive latter review further reported a positive relation between withdrawal rate and the relation between withdrawal rate and the size of the trials. The withdrawal rates size of the trials. The withdrawal rates varied slightly between treatment groups varied slightly between treatment groups in our study, with borderline statistical sigin our study, with borderline statistical significance for the higher rate of withdrawals nificance for the higher rate of withdrawals due to lack of efficacy in the placebo group, due to lack of efficacy in the placebo group, and a somewhat higher withdrawal rate and a somewhat higher withdrawal rate due to adverse events in the escitalopram due to adverse events in the escitalopram group. group.
Tolerability Tolerability
Escitalopram was well tolerated in this Escitalopram was well tolerated in this study, with prevalence rates of single study, with prevalence rates of single adverse symptoms comparable with those adverse symptoms comparable with those in studies of its use in depression (Wade in studies of its use in depression (Wade et al et al, 2002) . A favourable tolerability , 2002) . A favourable tolerability profile is important in the pharmacoprofile is important in the pharmacotherapy of this chronic disease, for which therapy of this chronic disease, for which 2 2 5 2 2 5 . placebo (analysis of covariance). Table 3  Table 3 Treatment-emergent adverse events with an incidence greater than 5% Treatment-emergent adverse events with an incidence greater than 5%
Placebo group Placebo group Insomnia Insomnia 11 (6) 11 (6) 17 (9) 17 (9) Dizziness Dizziness 9 (5) 9 (5) 13 (7) 13 (7) Rhinitis Rhinitis 9 (5) 9 (5) 13 (7) 13 (7) Sweating increased Sweating increased 3 (2) 3 (2) 11 (6) 11 (6) Ejaculation failure (men) Ejaculation failure (men) 0 0 6 (6) 6 (6) Libido decreased Libido decreased 2 (1) 2 (1) 10 (6) 10 (6) lengthy treatment may be required. Headlengthy treatment may be required. Headache was the adverse event with the highest ache was the adverse event with the highest incidence, and its incidence was similar incidence, and its incidence was similar in the two treatment groups. Nausea, in the two treatment groups. Nausea, increased sweating and sexual side-effects increased sweating and sexual side-effects occurred with a higher incidence during occurred with a higher incidence during escitalopram treatment. The efficacy/tolerability profile of escitalopram and the low withdrawal rate in this study make escitalopram a valuable pharmacotherapeutic option in the treatment of study make escitalopram a valuable pharmacotherapeutic option in the treatment of patients with social anxiety disorder. patients with social anxiety disorder.
LIMITATIONS LIMITATIONS
& & A high placebo response rate was found in this study.
A high placebo response rate was found in this study.
& & Given the chronic course of the disease, studies with a longer treatment duration Given the chronic course of the disease, studies with a longer treatment duration may be warranted to assess further potential improvements. may be warranted to assess further potential improvements.
& & The patient sample was selected to minimise comorbidity with other psychiatric
The patient sample was selected to minimise comorbidity with other psychiatric disorders in order to investigate effects of escitalopram specifically in social anxiety disorders in order to investigate effects of escitalopram specifically in social anxiety disorders. disorders.
